Physician

Karl Philip Roos, MD

According to 2025 Medicare claims, Karl Roos, MD (NPI: 1518004803) practices nephrology in the Mankato, MN market, with the plurality of this provider's patient population coming from Blue Earth, MN. This provider's primary affiliated billing organization is MANKATO CLINIC LTD (NPI: 1629044029; TIN: 410849339) and primary practice location at 56001-5066. Roos is affiliated with the Central Minnesota ACO, LLC (ACO ID: A2844), Stratum Med ACO (ACO ID: A4527), Mayo Clinic Community ACO, LLC (ACO ID: A4617), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Roos' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 511 traditional Medicare patients, billed 13,244 HCPCS/CPT codes, and received $245,870 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,498 prescription claims across 393 beneficiaries totaling $477,759 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 49 claims. Open Payments data shows 1 records totaling $13. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $105,253 to $245,870. Similarly, Part D prescription costs have moved sharply higher in recent years, from $108,530 to $477,759. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$139K$277K2015 Medicare payment: $105,253 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $112,928 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $135,046 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $157,252 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $243,603 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $236,341 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $277,150 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $250,255 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $257,772 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $245,870 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20152422,792$105,253
20162603,671$112,928
20172623,396$135,046
20183834,118$157,252
20195837,416$243,603
20205486,302$236,341
20215196,476$277,150
20224839,149$250,255
202349714,993$257,772
202451113,244$245,870

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$252K$504K2015 Drug cost: $108,530 (USD; Tot_Drug_Cst)2016 Drug cost: $90,072 (USD; Tot_Drug_Cst)2017 Drug cost: $154,887 (USD; Tot_Drug_Cst)2018 Drug cost: $182,641 (USD; Tot_Drug_Cst)2019 Drug cost: $268,446 (USD; Tot_Drug_Cst)2020 Drug cost: $201,527 (USD; Tot_Drug_Cst)2021 Drug cost: $205,626 (USD; Tot_Drug_Cst)2022 Drug cost: $291,650 (USD; Tot_Drug_Cst)2023 Drug cost: $504,483 (USD; Tot_Drug_Cst)2024 Drug cost: $477,759 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151761,108$108,530
20161991,179$90,072
20172041,169$154,887
20182781,585$182,641
20192761,680$268,446
20203031,820$201,527
20213441,952$205,626
20223802,106$291,650
20233902,217$504,483
20243932,498$477,759

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$2.8K$5.7K2017 Medicare payment: $880 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $4,252 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $5,300 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $5,675 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $762 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $1,880 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $941 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/R24$880
2018N/R70$4,252
2019N/R119$5,300
2020N/R135$5,675
2021N/RN/RN/R
2022N/R61$762
2023N/R95$1,880
2024N/R49$941

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more360642$90
83970Parathormone (parathyroid hormone) level219364$40
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's358624$12
36415Insertion of needle into vein for collection of blood sample232471$9
84100Phosphate level228385$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FarxigaDapagliflozin Propanediol845,627$103,395
Thiola EcTiopronin12360$91,581
JardianceEmpagliflozin332,070$40,277
CalcitriolCalcitriol50538,200$12,220
Potassium Citrate ErPotassium Citrate624,029$7,293

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodNN/R21$428
J7517Mycophenolate mofetil, oral, 250 mgNN/R15$313
J7507Tacrolimus, immediate release, oral, 1 mgNN/R13$200

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.1$13Ardelyx, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Karl Philip Roos, MD?

Tedicare shows public-source Medicare data for Karl Philip Roos, MD (NPI 1518004803), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Karl Philip Roos, MD have ACO affiliation data?

Karl Philip Roos, MD is shown with ACO affiliation data for Central Minnesota ACO, LLC (MSSP, ACO ID A2844), Stratum Med ACO (MSSP, ACO ID A4527), Mayo Clinic Community ACO, LLC (MSSP, ACO ID A4617), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Karl Philip Roos, MD?

Karl Philip Roos, MD is linked to MANKATO CLINIC LTD (billing NPI 1629044029) in the available physician profile data.

Does Karl Philip Roos, MD have Open Payments data?

Karl Philip Roos, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.